BRPI1011477A2 - 8-substituted quinolines and related analogues as sirtuin modulators - Google Patents

8-substituted quinolines and related analogues as sirtuin modulators

Info

Publication number
BRPI1011477A2
BRPI1011477A2 BRPI1011477A BRPI1011477A BRPI1011477A2 BR PI1011477 A2 BRPI1011477 A2 BR PI1011477A2 BR PI1011477 A BRPI1011477 A BR PI1011477A BR PI1011477 A BRPI1011477 A BR PI1011477A BR PI1011477 A2 BRPI1011477 A2 BR PI1011477A2
Authority
BR
Brazil
Prior art keywords
related analogues
substituted quinolines
sirtuin modulators
sirtuin
modulators
Prior art date
Application number
BRPI1011477A
Other languages
Portuguese (pt)
Inventor
Chib B Vu
Rebecca L Casaubon
Original Assignee
Sirtris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc filed Critical Sirtris Pharmaceuticals Inc
Publication of BRPI1011477A2 publication Critical patent/BRPI1011477A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1011477A 2009-03-02 2010-03-02 8-substituted quinolines and related analogues as sirtuin modulators BRPI1011477A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15674909P 2009-03-02 2009-03-02
PCT/US2010/025963 WO2010101949A1 (en) 2009-03-02 2010-03-02 8-substituted quinolines and related analogs as sirtuin modulators

Publications (1)

Publication Number Publication Date
BRPI1011477A2 true BRPI1011477A2 (en) 2016-03-22

Family

ID=42709991

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011477A BRPI1011477A2 (en) 2009-03-02 2010-03-02 8-substituted quinolines and related analogues as sirtuin modulators

Country Status (11)

Country Link
EP (1) EP2403833A4 (en)
JP (1) JP2012519211A (en)
KR (1) KR20110128908A (en)
CN (1) CN102414180A (en)
AU (1) AU2010221417A1 (en)
BR (1) BRPI1011477A2 (en)
CA (1) CA2754058A1 (en)
EA (1) EA201171098A1 (en)
IL (1) IL214943A0 (en)
MX (1) MX2011009213A (en)
WO (1) WO2010101949A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021938B1 (en) 2008-05-01 2015-10-30 Сертрис Фармасьютикалз, Инк. Quenolines and related analogs as sirtuin modulators
KR20110036602A (en) 2008-07-03 2011-04-07 서트리스 파마슈티컬즈, 인코포레이티드 Benzimidazole and related analogs as sirtuin modulators
AU2009295948B2 (en) 2008-09-29 2013-12-05 GlaxoSmithKline, LLC Quinazolinone, quinolone and related analogs as sirtuin modulators
US9556201B2 (en) 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
AU2012230503B2 (en) 2011-03-18 2016-07-07 Bayer Intellectual Property Gmbh N-(3-carbamoylphenyl)-1H-pyrazole-5-carboxamide derivatives and the use thereof for controlling animal pests
CN102250151B (en) * 2011-05-17 2013-11-06 中国科学院化学研究所 2-arimid-8-benzimidazol quinoline transition metal compound and preparation method and use thereof
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2014120166A (en) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи SUBSTITUTED Bicyclic AZA-HETEROCYCLES AND THEIR ANALOGUES AS SIRTUIN MODULATORS
EP2768834B1 (en) * 2011-10-20 2016-04-27 Glaxosmithkline LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
CA2865043A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
EP2922540A1 (en) * 2012-11-20 2015-09-30 F. Hoffmann-La Roche AG Substituted 1,6-naphthyridines
ES2723883T3 (en) 2013-03-14 2019-09-03 Merck Patent Gmbh Glycosidase inhibitors
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN105339368B (en) 2013-06-04 2017-08-15 拜耳制药股份公司 Imidazo [1,2 a] pyridine of 3 aryl substitution and application thereof
TWI529171B (en) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 1,7-naphthyridine derivatives
CA2923101A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
US10172915B2 (en) 2013-10-20 2019-01-08 Duke University Methods and compositions for activation of sirtuins with Annexin A1 peptides
JP6112724B2 (en) * 2013-10-31 2017-04-12 日本化薬株式会社 1,5-naphthyridine derivative and insecticide comprising the same as an active ingredient
EA028940B1 (en) * 2013-11-12 2018-01-31 Ф. Хоффманн-Ля Рош Аг PYRIDO[4,3-b]PYRAZINE-2-CARBOXAMIDES AS NEUROGENIC AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
TW201612161A (en) 2014-01-20 2016-04-01 Bayer Cropscience Ag Quinoline derivatives as insecticides and acaricides
WO2015124544A1 (en) 2014-02-19 2015-08-27 Bayer Pharma Aktiengesellschaft 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
KR20170005868A (en) 2014-05-23 2017-01-16 액티브 바이오테크 에이비 Novel compounds useful as s100-inhibitors
CN106817900A (en) * 2014-07-17 2017-06-09 默克专利有限公司 Novel naphthyridines and isoquinolin and its purposes as CDK8/19 inhibitor
ES2896400T3 (en) 2014-08-01 2022-02-24 Nuevolution As Active compounds against bromdomains
BR112017003658B1 (en) 2014-08-28 2022-12-06 Asceneuron Sa COMPOUND, MIXTURE, METHOD FOR INHIBITING A GLYCOSIDASE, AND PHARMACEUTICAL COMPOSITION
JP2017536396A (en) 2014-12-02 2017-12-07 バイエル・ファルマ・アクティエンゲゼルシャフト Heteroaryl substituted imidazo [1,2-a] pyridines and uses thereof
CN104592109A (en) * 2015-01-19 2015-05-06 湖南华腾制药有限公司 Method for preparing 8-bromoquinoline derivative
AU2016217874A1 (en) * 2015-02-11 2017-08-10 Basilea Pharmaceutica International AG Substituted mono- and polyazanaphthalene derivatives and their use
EP3585783A2 (en) 2016-02-25 2020-01-01 Asceneuron SA Sulfoximine glycosidase inhibitors
EP3419976B1 (en) 2016-02-25 2021-04-07 Asceneuron SA Acid addition salts of piperazine derivatives
AU2017222964B2 (en) 2016-02-25 2020-01-02 Asceneuron S. A. Glycosidase inhibitors
US11612599B2 (en) 2016-02-25 2023-03-28 Asceneuron Sa Glycosidase inhibitors
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
EP3841093B1 (en) 2018-08-22 2023-06-21 Asceneuron SA Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors
US11731972B2 (en) 2018-08-22 2023-08-22 Asceneuron Sa Spiro compounds as glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2020039028A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Tetrahydro-benzoazepine glycosidase inhibitors
EP3930849B1 (en) * 2019-02-28 2025-02-19 Kezar Life Sciences Thiazole derivatives as protein secretion inhibitors
CN110964011B (en) * 2019-12-16 2022-06-21 诚达药业股份有限公司 Synthetic method of 8-chloro-1, 7-naphthyridine-3-formaldehyde
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
BR112023000047A2 (en) 2020-07-02 2023-03-14 Incyte Corp TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (en) 2021-02-25 2023-07-05 Incyte Corp SPIROCYCLIC LACTAMS AS JAK2 INHIBITORS V617F
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
KR20240163688A (en) 2022-03-17 2024-11-19 인사이트 코포레이션 Tricyclic urea compounds as JAK2 V617F inhibitors
WO2024059216A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same
WO2024059212A2 (en) * 2022-09-15 2024-03-21 Vanderbilt University 6,6 western core compounds as mglu5 negative allosteric modulators and methods of making and using the same
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
AU2024264503A1 (en) * 2023-04-23 2025-12-04 Suzhou Genhouse Bio Co., Ltd. Amide compound, pharmaceutical composition comprising same, and use thereof
CN117362286B (en) * 2023-12-08 2024-03-12 清华大学 Compounds with SIRT6 agonistic activity and their uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU740745B2 (en) * 1997-12-11 2001-11-15 Biochem Pharma Inc. Antiviral compounds
FR2827599A1 (en) * 2001-07-20 2003-01-24 Neuro3D Treating central nervous system disorders, e.g. anxiety, depression, schizophrenia or pain, using new or known 2-substituted quinoline or quinoxaline derivatives having xanthenuric acid modulating action
SE0103649D0 (en) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
CA2518398A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
EP1773834A2 (en) * 2004-08-03 2007-04-18 Serenex, Inc. 2, 8-disubstituted naphthyridine derivatives
WO2006094237A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators
BRPI0908396A2 (en) * 2008-02-28 2019-03-06 Novartis Ag quinolines as farnesyl pyrophosphate synthase inhibitors
EA021938B1 (en) * 2008-05-01 2015-10-30 Сертрис Фармасьютикалз, Инк. Quenolines and related analogs as sirtuin modulators
AU2009295948B2 (en) * 2008-09-29 2013-12-05 GlaxoSmithKline, LLC Quinazolinone, quinolone and related analogs as sirtuin modulators

Also Published As

Publication number Publication date
JP2012519211A (en) 2012-08-23
AU2010221417A1 (en) 2011-09-22
MX2011009213A (en) 2011-12-14
EP2403833A1 (en) 2012-01-11
EP2403833A4 (en) 2012-08-29
EA201171098A1 (en) 2012-04-30
CA2754058A1 (en) 2010-09-10
WO2010101949A1 (en) 2010-09-10
CN102414180A (en) 2012-04-11
IL214943A0 (en) 2011-11-30
KR20110128908A (en) 2011-11-30

Similar Documents

Publication Publication Date Title
BRPI0913117A2 (en) imidazopyridine and related analogues as sirtuin modulators
IL214943A0 (en) 8-substituted quinolines and related analogs as sirtuin modulators
BRPI0919389A2 (en) chromone analogues as sirtuin modulators
BRPI0914006A2 (en) benzimidazoles and related analogues as sirtuin modulators
BRPI0922180A2 (en) insoindolinone and related analogues as modulators of sirtuin
BRPI0919625A2 (en) pyriridine, bicyclic pyridine and related analogues as sirtuin modulators
BRPI0922597A8 (en) phthalazinone and related analogues as sirtuin modulators
BR112014009531A8 (en) substituted bicyclic azaheterocycles and analogues as sirtuin modulators
EP2413730A4 (en) TRACTION ELEMENTS
BR112014009348A2 (en) bicyclic substituted azaheterocycles and analogues as sirtuin modulators
EP2435504A4 (en) FLAVONOID HYDROGEL
BRPI1011694A2 (en) category similators
BRPI1014982A2 (en) suspension device
IL208997A0 (en) Quinolines and related analogs as sirtuin modulators
EP2460425A4 (en) HELMET
DK2246017T3 (en) Absorbent object
BRPI0915867A2 (en) 4-phenoxymethylpiperidines as modulators of gpr119 activity
EP2499661A4 (en) PHOTORESERVE SIMULATION
BRPI1011310A2 (en) aircraft
BRPI1008744A2 (en) hydrotreating of cabohydrates
BR112012010242A2 (en) heteroarylpiperidine and heteroarylpiperazine derivatives
BRPI1007368A2 (en) misting device
BRPI1009428A2 (en) Substituted 3-aminoisoxazolopyridine as kcnq2 / 3 modulators
FR2947857B1 (en) DESHUILEUR ARRANGEMENT
BRPI1008963A2 (en) Substituted 2-mercapto-3-aminopyridine as kcnq2 / 3 modulators

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]